CRL 250117 160.00P (CRL250117P160000) Stock Options, News & Quotes

0.72
-0.93-56.36%

15min DelayTrading Jan 2 10:32 ET

0.72High0.72Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

韭菜变主力

Dec 30, 2024 01:18

$Charles River (CRL.US)$ In this almost everything rally market with stocks doubling easily, biomedical research companies have found growth is extremely hard to come by, and P/E has been stuck going nowhere.

Moomoo AI

Feb 29, 2024 01:09

The CEOs of both Wheeler Bio and Charles River express optimism about the partnership, believing that the integration of discovery CRO and CDMO workflows will speed up the path to first-in-human trials and bring new treatments to patients faster.

Press Release: Wheeler Bio Seals Agreement With Charles River to Offer Portable CMC(R) to Discovery Clients to Accelerate Their Journey to First-in-Human Use

Moomoo AI

Feb 26, 2024 04:44

Insider's recent share sale, even below current price, suggests satisfaction with lower valuation. Despite high insider ownership, this selling hints at caution. The company also has 1 warning sign worth noting before buying shares.

Have Charles River Laboratories International Insiders Been Selling Stock?

Moomoo AI

Feb 16, 2024 09:18

EPS growth outshines the yearly share price gain of 12%, indicating market caution towards the stock. Despite sell-off, long term shareholders gained 12% annually over five years, suggesting the sell-off might be a growth opportunity.

Charles River Laboratories International (NYSE:CRL) Stock Performs Better Than Its Underlying Earnings Growth Over Last Five Years

Moomoo AI

Jan 17, 2024 06:06

Charles River Laboratories International's high P/E ratio is concerning due to its lower than expected growth. Investors seem more bullish than analysts, but current prices may not be sustainable without significant improvement.

Getting In Cheap On Charles River Laboratories International, Inc. (NYSE:CRL) Is Unlikely